BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Imamura M, Morimoto T, Nomura T, Michishita S, Nishimukai A, Higuchi T, Fujimoto Y, Miyagawa Y, Kira A, Murase K, Araki K, Takatsuka Y, Oh K, Masai Y, Akazawa K, Miyoshi Y. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Oncol 2018;16:26. [PMID: 29433529 DOI: 10.1186/s12957-018-1325-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Manafi-farid R, Ataeinia B, Ranjbar S, Jamshidi Araghi Z, Moradi MM, Pirich C, Beheshti M. ImmunoPET: Antibody-Based PET Imaging in Solid Tumors. Front Med 2022;9:916693. [DOI: 10.3389/fmed.2022.916693] [Reference Citation Analysis]
2 Anoop TM, Joseph P R, Soman S, Chacko S, Mathew M. Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study. World J Clin Oncol 2022; 13(6): 529-539 [DOI: 10.5306/wjco.v13.i6.529] [Reference Citation Analysis]
3 Zhao W, Li X, Wang W, Chen B, Wang L, Zhang N, Wang Z, Yang Q. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer. Dis Markers 2021;2021:5529106. [PMID: 34621407 DOI: 10.1155/2021/5529106] [Reference Citation Analysis]
4 Lugat A, Hulo P, Ansquer C, Touchefeu Y, Mirallié E, Bennouna J, Drui D. Carcinoembryonic Antigen Increase in a Patient with Colon Cancer Who Have Achieved Complete Remission and Negative 18F-FDG PET/CT: Don't Forget the Thyroid! Curr Oncol 2021;28:2987-92. [PMID: 34436027 DOI: 10.3390/curroncol28040261] [Reference Citation Analysis]
5 Kim JY, Jeon E, Kwon S, Jung H, Joo S, Park Y, Lee SK, Lee JE, Nam SJ, Cho EY, Park YH, Ahn JS, Im YH. Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer. Breast Cancer Res Treat 2021. [PMID: 34224056 DOI: 10.1007/s10549-021-06310-8] [Reference Citation Analysis]
6 Bechmann MB, Brydholm AV, Codony VL, Kim J, Villadsen R. Heterogeneity of CEACAM5 in breast cancer. Oncotarget 2020;11:3886-99. [PMID: 33196697 DOI: 10.18632/oncotarget.27778] [Reference Citation Analysis]
7 Gajdosova V, Lorencova L, Kasak P, Tkac J. Electrochemical Nanobiosensors for Detection of Breast Cancer Biomarkers. Sensors (Basel) 2020;20:E4022. [PMID: 32698389 DOI: 10.3390/s20144022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Rousseau C, Goldenberg DM, Colombié M, Sébille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Chauvet AF, Fresnel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodéré F. Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Nucl Med 2020;61:1205-11. [PMID: 32169921 DOI: 10.2967/jnumed.119.236000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Magzoub MM, Prunello M, Brennan K, Gevaert O. The impact of DNA methylation on the cancer proteome. PLoS Comput Biol 2019;15:e1007245. [PMID: 31356589 DOI: 10.1371/journal.pcbi.1007245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Lian M, Zhang C, Zhang D, Chen P, Yang H, Yang Y, Chen S, Hong G. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer. J Clin Lab Anal 2019;33:e22875. [PMID: 30843272 DOI: 10.1002/jcla.22875] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
11 Wang XM, Zhang Z, Pan LH, Cao XC, Xiao C. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients. Breast Cancer Res Treat 2019;174:375-85. [PMID: 30535933 DOI: 10.1007/s10549-018-05069-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
12 Fujimoto Y, Higuchi T, Nishimukai A, Miyagawa Y, Kira A, Ozawa H, Bun A, Imamura M, Miyoshi Y. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. J Surg Oncol 2018;118:228-37. [PMID: 29936704 DOI: 10.1002/jso.25125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]